The Transformative Pathology Program supports cancer research needs for high-quality tumour tissue, normal tissue, blood samples and their derivatives. It will coordinate the efforts of the Ontario Tumour Bank, the Ontario Cancer Biomarker Network and the Ontario Tumour Repository Network. The Program will provide a high quality collection and state-of-the-art storage infrastructure.
Transformative Pathology Program Fact Sheet
Lead Principal Investigator
Dr. John Bartlett
Dr. John Bartlett interviewed by ecancertv
HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer (December 17, 2015)